The BRICS Diabetes Drugs Market value is projected to reach US$ 86.96 Bn. at the end of the forecast period and it is expected to grow at the CAGR of 12.2%.BRICS Diabetes Drugs Market Overview:
Diabetes drugs are the medications that are used to treat diabetes mellitus type-1 and type-2 by dropping the blood glucose level of the body. There are various classes of drugs involved in the treatment of diabetes which is administered by oral route, intravenous, and subcutaneous routes. The increasing occurrence of diabetes, particularly type-2 diabetes, and the increasing demand for effective drug therapies for the treatment of diabetes are some of the factors expected to boost the diabetes drug market during the forecast period (2023-2029). Recent research analyses that metformin a common, generic type-2 diabetes medication used to manage blood sugar levels is associated with significantly lower COVID-19 death risk in women, but not in men.To know about the Research Methodology :- Request Free Sample Report The occurrence of diabetes is going up across the globe, because of increased life expectancy, shifting eating styles of individuals, and the rising incidence of obesity. Brazil’s diabetes drug market is witnessing a double-digit growth rate, while the Russian insulin market is also expected to show significant growth with a predictable 25 million patients in this region requiring diabetes treatment by 2029.
BRICS Diabetes Drugs Market Country Analysis:
India and China have the highest number of diabetics in the globe, as China is expected to have above 72 million diabetic patients by 2029 and also huge patient base in India has already focused on several pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to hold the market share in the Indian market for diabetes drugs. Therefore, the diabetes drug market in BRIC economies is expected to create significant growth opportunities in the future. BRIC countries hold a significant market share of the global market for diabetes drugs as they together account for 38% of the global occurrence of diabetes conditions. Because of improvements in living standards, the rising incidence of diabetes in BRIC is expected to closely 100 million patients by 2029, or about 40% of the world’s diabetic population. The slowdown of the pharma market growth in developed economies has focused investor interest on BRIC countries, where the diabetes drug market has promoted significantly from government initiatives for spreading patient awareness, and the subsequent increase in the approval of novel drugs such as incretin mimetics (Eli Lilly’s Byetta) and dipeptidyl inhibitors (Merck’s Januvia and Novartis’ Galvus). The report focuses on diabetes drugs market value at the BRICS countries of the world, which shows a countrywise development, including market size, share, revenue, and much more across the BRICS countries. The report has covered, capacity, production value, cost/profit, and supply/demand by statistical analysis. A brief analysis of drivers, restraints, opportunities, and challenges in the market is also covered with examples by countries. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. It also has covered the analysis of key player’s growth strategies, micro and macro analysis of markets, key developments, and key trends in the market.BRICS Diabetes Drugs Market Scope: Inquire before buying
Global BRICS Diabetes Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 38.84 Bn. Forecast Period 2023 to 2029 CAGR: 12.2% Market Size in 2029: US $ 86.96 Bn. Segments Covered: by Drug Type Injectable Drugs Insulin Exenatide Liragultide Pramlintide by Diabetes Type Type-1 Type-2 by Route of Administration Oral Subcutaneous Intravenous by Distribution Channel Online Pharmacies Hospital Pharmacies Retail Pharmacies BRICS Diabetes Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Diabetes Drugs Market Key Players
1.Abbott Laboratories 2.Aurobindo Pharma Ltd 3.Bayer Healthcare Ag 4.Biocon Ltd 5.Boehringer Ingelheim 6.Bristol-Myers Squibb 7.Dr. Reddy's Laboratories Ltd 8.Eli Lilly And Company 9.Glenmark Pharmaceuticals Ltd 10.Glaxosmithkline Plc 11.Lupin Ltd 12.Merck & Co. Inc. 13.Novo Nordisk A/S 14.Piramal Healthcare Ltd 15.Ranbaxy Laboratories Ltd 16.Roche Holding Ltd 17.Sanofi-Aventis 18.Shreya Life Sciences Pvt Ltd 19.Sun Pharma Industries Ltd 20.Takeda Pharmaceuticals Company 21.Zydus Cadila Healthcare Ltd 22.Medtronic 23.AstraZeneca Plc. 24.Lifescan 25.Terumo Medical Corporation Frequently Asked Questions: 1. Which region has the largest share in Global Diabetes Drugs Market? Ans: China region held the highest share in 2022. 2. What is the growth rate of Global Diabetes Drugs Market? Ans: The Global Diabetes Drugs Market is growing at a CAGR of 12.2% during forecasting period 2023-2029. 3. What is scope of the Global Diabetes Drugs market report? Ans: Global Diabetes Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Diabetes Drugs market? Ans: The important key players in the Global Diabetes Drugs Market are – Dr. Reddy's Laboratories Ltd, Eli Lilly And Company, Glenmark Pharmaceuticals Ltd, Glaxosmithkline Plc, Lupin Ltd, Merck & Co. Inc., Novo Nordisk A/S, Piramal Healthcare Ltd, Ranbaxy Laboratories Ltd, Roche Holding Ltd, Sanofi-Aventis, Shreya Life Sciences Pvt Ltd, Sun Pharma Industries Ltd, Takeda Pharmaceuticals Company, Zydus Cadila Healthcare Ltd, Medtronic, AstraZeneca Plc., Lifescan, and Terumo Medical Corporation 5. What is the study period of this market? Ans: The Global Diabetes Drugs Market is studied from 2022 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: BRICS Diabetes Drugs Market Size, by Market Value (US$ Bn) 3.1. BRICS Market Segmentation 3.2. BRICS Market Segmentation Share Analysis, 2022 3.3. Geographical Snapshot of the Diabetes Drugs Market 3.4. Geographical Snapshot of the Diabetes Drugs Market, By Manufacturer share 4. BRICS Diabetes Drugs Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.2. Restraints 4.1.3. Opportunities 4.1.4. Challenges 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the BRICS Diabetes Drugs Market 5. Supply Side and Demand Side Indicators 6. BRICS Diabetes Drugs Market Analysis and Forecast, 2022-2029 6.1. BRICS Diabetes Drugs Market Size & Y-o-Y Growth Analysis. 7. BRICS Diabetes Drugs Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 7.1.1. Injectable Drugs 7.1.1.1. Insulin 7.1.1.2. Exenatide 7.1.1.3. Liragultide 7.1.1.4. Pramlintide 7.1.2. Oral Drugs 7.1.2.1. Biguanides 7.1.2.2. Sulfonylureas 7.1.2.3. Meglitinides and D-Phenylalanine Derivatives 7.1.2.4. Thiazolidinediones 7.1.2.5. DPP-4 Inhibitors 7.1.2.6. Alpha-glucosidase Inhibitors 7.1.2.7. Bile Acid Sequestrants 7.1.2.8. Others (Combination Pills) 7.2. Market Size (Value) Estimates & Forecast By Diabetes Type, 2022-2029 7.2.1. Type-1 7.2.2. Type-2 7.3. Market Size (Value) Estimates & Forecast By Route of Administration, 2022-2029 7.3.1. Oral 7.3.2. Subcutaneous 7.3.3. Intravenous 7.4. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 7.4.1. Online Pharmacies 7.4.2. Hospital Pharmacies 7.4.3. Retail Pharmacies 8. BRICS Diabetes Drugs Market Analysis and Forecasts, By Country 8.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 8.1.1. Brazil 8.1.2. Russia 8.1.3. India 8.1.4. China 8.1.5. South Africa 9. Brazil Diabetes Drugs Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 9.1.1. Injectable Drugs 9.1.1.1. Insulin 9.1.1.2. Exenatide 9.1.1.3. Liragultide 9.1.1.4. Pramlintide 9.1.2. Oral Drugs 9.1.2.1. Biguanides 9.1.2.2. Sulfonylureas 9.1.2.3. Meglitinides and D-Phenylalanine Derivatives 9.1.2.4. Thiazolidinediones 9.1.2.5. DPP-4 Inhibitors 9.1.2.6. Alpha-glucosidase Inhibitors 9.1.2.7. Bile Acid Sequestrants 9.1.2.8. Others (Combination Pills) 9.2. Market Size (Value) Estimates & Forecast By Diabetes Type, 2022-2029 9.2.1. Type-1 9.2.2. Type-2 9.3. Market Size (Value) Estimates & Forecast By Route of Administration, 2022-2029 9.3.1. Oral 9.3.2. Subcutaneous 9.3.3. Intravenous 9.4. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 9.4.1. Online Pharmacies 9.4.2. Hospital Pharmacies 9.4.3. Retail Pharmacies 10. Russia Diabetes Drugs Market Analysis and Forecasts, 2022-2029 10.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 10.2. Market Size (Value) Estimates & Forecast By Diabetes Type, 2022-2029 10.3. Market Size (Value) Estimates & Forecast By Route of Administration, 2022-2029 10.4. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 11. India Diabetes Drugs Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By Diabetes Type, 2022-2029 11.3. Market Size (Value) Estimates & Forecast By Route of Administration, 2022-2029 11.4. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 12. China Diabetes Drugs Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By Diabetes Type, 2022-2029 12.3. Market Size (Value) Estimates & Forecast By Route of Administration, 2022-2029 12.4. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 13. South Africa Diabetes Drugs Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By Diabetes Type, 2022-2029 13.3. Market Size (Value) Estimates & Forecast By Route of Administration, 2022-2029 13.4. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 14. Competitive Landscape 14.1. Geographic Footprint of Major Players in the BRICS Diabetes Drugs Market 14.2. Competition Matrix 14.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 14.2.2. New Product Launches and Product Enhancements 14.2.3. Market Consolidation 14.2.3.1. M&A by Regions, Investment and Verticals 14.2.3.2. M&A, Forward Integration and Backward Integration 14.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 14.3. Company Profile : Key Players 14.3.1. Abbott Laboratories 14.3.1.1. Company Overview 14.3.1.2. Financial Overview 14.3.1.3. Geographic Footprint 14.3.1.4. Product Portfolio 14.3.1.5. Business Strategy 14.3.1.6. Recent Developments 14.3.2. Aurobindo Pharma Ltd 14.3.3. Bayer Healthcare Ag 14.3.4. Biocon Ltd 14.3.5. Boehringer Ingelheim 14.3.6. Bristol-Myers Squibb 14.3.7. Dr. Reddy's Laboratories Ltd 14.3.8. Eli Lilly And Company 14.3.9. Glenmark Pharmaceuticals Ltd 14.3.10. Glaxosmithkline Plc 14.3.11. Lupin Ltd 14.3.12. Merck & Co. Inc. 14.3.13. Novo Nordisk A/S 14.3.14. Piramal Healthcare Ltd 14.3.15. Ranbaxy Laboratories Ltd 14.3.16. Roche Holding Ltd 14.3.17. Sanofi-Aventis 14.3.18. Shreya Life Sciences Pvt Ltd 14.3.19. Sun Pharma Industries Ltd 14.3.20. Takeda Pharmaceuticals Company 14.3.21. Zydus Cadila Healthcare Ltd 14.3.22. Medtronic 14.3.23. AstraZeneca Plc. 14.3.24. Lifescan 14.3.25. Terumo Medical Corporation 15. Primary Key Insights